RASA1
protein-codingRAS p21 protein activator 1, the group of Pleckstrin homology domain containing|SH2 domain containing|C2 and RasGAP domain containing
Gene summary
The protein encoded by this gene is located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with basal cell carcinomas. Mutations also have been associated with hereditary capillary malformations (CM) with or without arteriovenous malformations (AVM) and Parkes Weber syndrome. Alternative splicing results in two isoforms where the shorter isoform, lacking the N-terminal hydrophobic region but retaining the same activity, appears to be abundantly expressed in placental but not adult tissues. [provided by RefSeq, May 2012]
- RASA
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~124.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0008535
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0020783
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0012017
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018997
Submitter: ClinGen
There have been multiple reported cases in the literature showing that RASA1 variants can cause cardiovascular anomalies such as capillary malformation-arteriovenous malformation syndrome (CM-AVM)(Ilari, Agosta, & Bacino, 2016; Macmurdo et al., 2016). These studies suggest that these patients may possess clinical features of Noonan syndrome (NS). However, patients with additional phenotypes such as hypotonia and severe ID all possess secondary causes of disease apart from RASA1 variation. Therefore, there is no convincing genetic evidence that supports the association of RASA1 and NS. In fact, RASA1 should most likely only be associated with cardiovascular anomalies. RASA1’s association with NS is Disputed. The ClinGen RASopathy Expert Panel found no evidence associating RASA1 with cardiofaciocutaneous syndrome, Costello syndrome, NS with loose anagen hair, or NS with multiple lentigines. This curation was approved by the ClinGen RASopathy Gene Curation Expert Panel on 6/7/18 (SOP Version 5).
Inheritance Pattern: AD
Disease ID:MONDO:0020783
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0020783
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0020783
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0020783
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Musculoskeletal
Intervention: Cardiovascular
Rationale: Life-threatening complications of arteriovenous malformations and arteriovenous fistulas can include bleeding, congestive heart failure, and/or neurologic consequences, and surveillance may allow early detection and medical/surgical management, which may decrease morbidity/mortality
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RASA1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_002890.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 12 | 361 | 374 | ||
| missense | 4 | 3 | 622 | 74 | 2 | 705 |
| nonsense | 56 | 10 | 2 | 68 | ||
| start loss | 1 | 1 | ||||
| frameshift | 125 | 37 | 1 | 163 | ||
| splice donor/acceptor (+/-2bp) | 22 | 52 | 10 | 84 | ||
| Total | 207 | 103 | 648 | 435 | 2 | 1395 |
Highest pathogenic variant AF is 0.0000065737577
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_002881.1 | 25 | MANE Select | |
| Ensembl | ENSP00000274376.6 | 25 | MANE Select | |
| RefSeq | NP_072179.1 | 25 | Standard | |
| Ensembl | ENSP00000411221.2 | 25 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| rasa1b | Danio rerio | Structure: hindbrain Quality: increased process quality abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Axon guidance - Homo sapiens (human)
- Ras signaling pathway - Homo sapiens (human)
- MAPK signaling pathway - Homo sapiens (human)
- Androgen Receptor Network in Prostate Cancer
- PDGF Pathway
Biological Process
- MAPK cascade
- mitotic cytokinesis
- vasculogenesis
- negative regulation of cell-matrix adhesion
- negative regulation of cell adhesion
Molecular Function
- phosphotyrosine residue binding
- GTPase activity
- GTPase activator activity
- signaling receptor binding
- protein binding
Cellular Component
- ruffle
- cytoplasm
- cytosol
- plasma membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000274376
- Coding exons
- 25
- Length
- 124044
- Individuals with no LoFs
- 125738
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 10
- Defined
- 125748
- p
- 0.0000398
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.10 | 369 | 579 | 0.638 | 0.0000302 | 6810 |
| Missense (PolyPhen) | 114 | 247.95 | 0.45977 | 2897 | ||
| Synonymous | -1.46 | 226 | 200 | 1.13 | 0.00000998 | 2044 |
| Loss of Function | 6.83 | 3 | 60.1 | 0.0499 | 0.00000345 | 702 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00017 | 0.00016 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000053 | 0.000053 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1. {ECO:0000269|PubMed:11389730, ECO:0000269|PubMed:8360177}.;
- Disease
- DISEASE: Note=Mutations in the SH2 domain of RASA seem to be oncogenic and cause basal cell carcinomas.; DISEASE: Capillary malformation-arteriovenous malformation (CMAVM) [MIM:608354]: A disorder characterized by atypical capillary malformations that are multiple, small, round to oval in shape and pinkish red in color. These capillary malformations are associated with either arteriovenous malformation, arteriovenous fistula, or Parkes Weber syndrome. {ECO:0000269|PubMed:14639529, ECO:0000269|PubMed:24038909}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Parkes Weber syndrome (PKWS) [MIM:608355]: Disorder characterized by a cutaneous flush with underlying multiple micro- arteriovenous fistulas, in association with soft tissue and skeletal hypertrophy of the affected limb. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.135
Intolerance Scores
- LoFtool
- 0.134
- RVIS EVS
- -0.82
- RVIS percentile EVS
- 11.88
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.968
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |